A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous sites

INTRODUCTION: Methods to induce T cell responses to protein vaccines have not been optimized. The immunostimulant AS15 has been administered with the recombinant MAGE-A3 protein (recMAGE-A3) i.m. but not i.d. or s.c. This study tests hypotheses that the i.d./s.c. route is safe and will increase CD4(...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancer Immunol Immunother
Päätekijät: Slingluff, Craig L., Petroni, Gina R., Olson, Walter C., Smolkin, Mark E., Chianese-Bullock, Kimberly A., Mauldin, Ileana S., Smith, Kelly T., Deacon, Donna H., Varhegyi, Nikole E., Donnelly, Sean B., Reed, Caroline M., Scott, Kristy, Galeassi, Nadejda V., Grosh, William W.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Springer Berlin Heidelberg 2015
Aiheet:
Original Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5010424/
https://ncbi.nlm.nih.gov/pubmed/26581199
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-015-1770-9
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia